December 23, 2005
Par Pharmaceutical Receives Final Approval to Market Generic Cefzil^® Tablets

December 22, 2005
Par to Acquire Eight Generic Products

December 19, 2005
New Antibiotic Candidate Shows Promise in Treating Clostridium Difficile-associated Diarrhea (CDAD)

December 19, 2005
Patients with HIV-associated Wasting Gain More Weight with Concentrated Form of Megestrol Acetate, Study Shows

December 16, 2005
Par to Distribute Generic Versions of AUGMENTIN^® AND AMOXIL^®

December 15, 2005
Par Pharmaceutical begins Shipment of Generic ADOXA^®

December 5, 2005
Par Pharmaceutical's Partner Receives Final Approval to Market Ribavirin Tablets

December 1, 2005
Par Pharmaceutical Receives Tentative Approval of Generic Dostinex^®

November 21, 2005
Par Pharmaceutical Receives Approval and Marketing Exclusivity for Ondansetron Hydrochloride Orally Disintegrating Tablets

November 03, 2005
Par Announces Agreement with Valeant to Promote Cesamet

October 24, 2005
Par Announces Strategic Alliance with MN Pharmaceuticals

October 20, 2005
Par Announces Tentative Approval of Ribavirin Tablets

September 20, 2005
Par Pharmaceutical Announces Promotions and Executive Staff Reorganization

September 14, 2005
Par Pharmaceutical Receives Approval to Market Generic Arava™

September 1, 2005
Par Pharmaceutical's Partner Receives Final Approval to Market Mirtazapine Orally Disintegrating Tablets

August 29, 2005
Par Pharmaceutical Receives Final Approval to Market Generic Questran^® Powder and Questran^® Light Powder for Oral Suspension

August 3, 2005
Par Pharmaceutical Terminates Partnership with Advancis Pharmaceutical

August 3, 2005
Par Pharmaceutical Recieves Final Approval to Market Clonazepam Orally Disintegrating Tablets

July 27, 2005
Par Pharmaceutical Announces Court Ruling on Ondanestron Hydrochloride Orally Disintegrating Tablets

July 26, 2005
Par Pharmaceutical Announces Results of Phase II Proof-of-Concept Study with Concentrated MEGESTROL ACETATE Oral Suspension

July 6, 2005
Par Pharmaceutical Announces FDA Approval of Megace ES for Anorexia, Cachexia, or an Unexplained, Significant Weight Loss in Patients with a Diagnosis of AIDS

June 17, 2005
Par Pharmaceutical Receives Tentative Approval of Ondanestron Hydrochloride Orally Disintegrating Tables

June 15, 2005
Advancis Pharmaceutical Announces Results from Adult/Adolescent Amoxicillin PULSYS Phase III Trial

May 3, 2005
Par Pharmaceutical Announces Equity Investment in Optimer Pharmaceuticals

April 22, 2005
Par Pharmaceutical Receives Approval to Market Generic Ultracet®

April 18, 2005
FDA Extends PDUFA Date for Megace® ES to July 29, 2005

March 28, 2005
Par Pharmaceutical to Present at Lehman Brothers Eighth Annual Global Healthcare Conference

February 23, 2005
Par Pharmaceutical to Present at Leerink Swann & Co. Inaugural Health Care Conference

February 3, 2005
Par Pharmaceutical to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference

February 1, 2005
Par Pharmaceutical to Market Verapamil Hydrochloride Extended Release Tablets

January 20, 2005
Par Pharmaceutical to Present at the Piper Jaffray Healthcare Conference

January 11, 2005
Par Pharmaceutical Names John A. MacPhee Senior Vice President, Branded Marketing and Sales

Archived copies of news releases issued since January 2003 are available on line, grouped by year of release: